Biotech News

Pediatrix Medical Group Announces $250 Million Share Repurchase Program

Pediatrix Medical Group, Inc. (MD)Pediatrix Medical Group, Inc.2025-08-18 20:30 ESTCompany update

FORT LAUDERDALE, Fla. --(BUSINESS WIRE)--Aug. 18, 2025-- Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today announced that its Board of Directors has authorized a share repurchase program of up to $250 million of the Company’s outstanding common stock.

Open original release

Related news

MDPediatrix Medical Group, Inc.2026-06-03 20:30 EST

Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology

MDPediatrix Medical Group, Inc.2026-05-05 10:00 EST

Pediatrix Medical Group Reports First Quarter Results

MDPediatrix Medical Group, Inc.2026-04-20 10:45 EST

Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026

MDPediatrix Medical Group, Inc.2026-03-26 20:30 EST

Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine

MDPediatrix Medical Group, Inc.2026-03-24 21:10 EST

Pediatrix Welcomes Two Nationally Renowned Physician Leaders

MDPediatrix Medical Group, Inc.2026-02-23 11:00 EST

Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology

MDPediatrix Medical Group, Inc.2026-02-19 11:00 EST

Pediatrix Medical Group Reports Fourth Quarter Results

MDPediatrix Medical Group, Inc.2026-02-09 11:45 EST

Pediatrix Medical Group 2025 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 19, 2026

MDPediatrix Medical Group, Inc.2025-11-03 11:00 EST

Pediatrix Medical Group Reports Third Quarter Results

MDPediatrix Medical Group, Inc.2025-10-21 10:45 EST

Pediatrix Medical Group 2025 Third Quarter Conference Call/Webcast Scheduled for Monday, November 3, 2025

View all latest news

Pediatrix Medical Group, Inc.

Pediatrix Medical Group is a physician-led healthcare services company focused on newborn, maternal-fetal, and pediatric care. Its business is centered on clinical service delivery rather than biotech or devices.

Recent company news

MDBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

MDQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

MDMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

MDAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

MDGSK plc2026-07-22 11:21 EST

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Stock data

Close: 25.58 USD
Market cap: 1.79B USD
Exchange: NYSE
Sector: Biopharma
Location: United States